STC-15, a derivate of STM2457, is a METTL3 inhibitor that has been reported to reduce acute myeloid leukaemia (AML) cell growth and increase survival in in vivo AML mouse models, with similar results identified in other cancer cell lines [78]. Here, METTL3 is linked to cancer.